Pharma Two B and Hepion Pharmaceuticals Announce Merger
KIRYAT ONO, ISRAEL and EDISON, N.J. — Pharma Two B Ltd., a leading late-stage pharmaceutical company focused on treating Parkinson’s Disease, has officially announced its merger with Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA), which specializes in addressing chronic liver diseases. They have filed a registration statement on Form F-4 with the U.S. Securities and Exchange Commission (SEC).
Details of the Registration Statement
This registration statement includes a proxy statement/prospectus about their proposed merger, based on the definitive agreement recently established between the two companies. The Merger Agreement marks a significant advancement aimed at strengthening the product portfolios of both organizations.
The Path Forward
Earlier this year, Pharma Two B revealed its intention to become a publicly traded company on Nasdaq through this partnership with Hepion. Both companies have secured board approval for the transaction, which is expected to be completed by the end of the year, subject to stockholder approval and regulatory clearances.
Anticipated Benefits of the Merger
The merger is designed to create a powerful combined entity under the Pharma Two B brand, leveraging the innovative drug development capabilities of both companies. This strategy is anticipated to enhance research efforts and expedite the market readiness of their therapeutic candidates.
Background on Pharma Two B
Pharma Two B is committed to improving patients' quality of life by developing innovative combination medications for neurological disorders, specifically addressing unmet treatment needs. Their flagship product, P2B001, aims to provide significant clinical benefits while ensuring patient safety and convenience. This unique formulation consists of a low-dose combination of pramipexole and rasagiline, both of which are established treatments for Parkinson’s Disease.
Clinical Insights
P2B001 has shown promising outcomes in clinical trials, demonstrating comparable efficacy to existing therapies while minimizing side effects typically associated with standard dosages. This positions it as a potential first-line treatment for patients with Parkinson’s Disease.
Insight on Hepion Pharmaceuticals
Hepion is recognized as an innovative biopharmaceutical company dedicated to developing therapies for non-alcoholic steatohepatitis (NASH) and other liver-related conditions. Their leading investigational drug, rencofilstat, targets various complications related to liver disease and is a cornerstone of their therapeutic strategy.
Recent Strategic Initiatives
In response to a competitive market, Hepion's management has implemented reforms to ensure liquidity, including the discontinuation of their ASCEND-NASH clinical trial. These changes are aimed at maximizing the company’s existing portfolio for the benefit of its shareholders.
Future Expectations
The merger is set to capitalize on the complementary strengths of both Pharma Two B and Hepion, potentially leading to significant advancements in treatments for Parkinson’s Disease and chronic liver conditions. The combined entity will not only improve operational efficiency but also enhance the ability to bring innovative therapies to market more effectively.
Frequently Asked Questions
What is the main focus of Pharma Two B?
Pharma Two B is dedicated to developing innovative combination drugs for neurological disorders, particularly Parkinson's Disease.
What is the proposed merger between Pharma Two B and Hepion?
The merger seeks to combine resources and expertise to enhance drug development capabilities and streamline the path to market for their respective therapies.
What therapeutic area is Hepion Pharmaceuticals focused on?
Hepion specializes in developing therapies for chronic liver diseases, including treatments for NASH and hepatocellular carcinoma.
What is P2B001?
P2B001 is an investigational drug from Pharma Two B that combines low doses of pramipexole and rasagiline for the treatment of Parkinson’s Disease.
When is the merger expected to close?
The merger is expected to close by the fourth quarter of the year, pending necessary approvals from stockholders and regulatory bodies.
